; or (B) which the applicant with respect to the patent was required to disclose under section 202(c)(6) of title 35, United States Code, in the application for the patent. (6) Secretary The term Secretary means the Secretary of Health and Human Services. 4. National Academy of Medicine study on determining a reasonable drug price (a) In general Not later than 60 days after the date of enactment of this Act, the Secretary shall seek to enter into a contract with the National Academy of Medicine (referred to in this section as the Academy ) under which the Academy agrees to study— (1) how best to determine the reasonableness of a drug’s manufacturer list price and retail price and develop at least 1 framework for determining the reasonableness of a drug’s manufacturer list price and retail price taking into consideration— (A) affordability of the drug to payers, purchasers, and patients across wide market segments in a manner that ensures equitable access; (B) investment by the National Institutes of Health or any other Federal Government entity in the development of the drug; (C) inclusion of research funded by the National Institutes of Health or other Federal Government entity in the development of the drug; (D) manufacturer research and development costs as shown on the manufacturer’s Federal tax filing under sections 41 and 174 of the Internal Revenue Code of 1986; (E) investment and the rate of return needs for the drug manufacturer; (F) market for the drug; (G) the cost of production and distribution of the drug; (H) the price of the drug in other similar, industrialized countries; (I) estimated global and domestic sales of the drug; (J) gross and net expenditures by public payers for coverage of the drug under Federal health programs, to the extent available; and (K) any additional information the Academy determines appropriate